| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Not applicable. 13,14-Dihydro-15-keto PGF1alpha is an inactive metabolite of prostaglandin F1alpha (PGF1alpha). It does not have significant biological activity at prostaglandin receptors. The "target" is analytical: the compound is used as a standard to measure the concentration of PGF1alpha and its metabolism in biological samples. The formation of this metabolite from PGF1alpha is catalyzed by the enzymes 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and delta13,14-reductase.
|
|---|---|
| ln Vitro |
13,14-Dihydro-15-keto PGF1alpha is a metabolite of PGF1alpha produced by the sequential action of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and delta13,14-reductase. The compound has significantly reduced biological activity compared to the parent PGF1alpha due to the reduction of the C-13,14 double bond and oxidation of the C-15 hydroxyl group. It serves primarily as an analytical standard for mass spectrometry-based quantification of PGF1alpha and its metabolic profile in biological matrices such as plasma, urine, and tissue homogenates. No specific pharmacological activity is reported.
|
| ln Vivo |
No in vivo data is applicable, as 13,14-Dihydro-15-keto PGF1alpha is an inactive metabolite, not a pharmacologically active drug. In vivo, it is produced endogenously from PGF1alpha through normal metabolic pathways. The levels of this metabolite in urine or plasma can be measured as an indicator of PGF1alpha production and metabolism in physiological or pathological states. It is not administered exogenously to produce a pharmacological effect; rather, it is used as an analytical standard for quantitative bioanalysis.
|
| Enzyme Assay |
Not applicable. 13,14-Dihydro-15-keto PGF1alpha is an analytical standard, not a test compound in non-cellular enzyme assays. For metabolite detection in biological samples, a typical protocol involves sample preparation: 50-100 uL of plasma or urine is mixed with a deuterated internal standard (e.g., 13,14-dihydro-15-keto PGF1alpha-d4). Samples are acidified to pH 3-4 with formic acid, and prostaglandins are extracted using solid-phase extraction (SPE) with C18 cartridges. The eluate is dried, reconstituted, and analyzed by LC-MS/MS in negative ion mode with multiple reaction monitoring. Standard curves are prepared using known concentrations of the metabolite standard.
|
| Cell Assay |
Not applicable. 13,14-Dihydro-15-keto PGF1alpha is an analytical standard, not a compound used in cell-based assays as a pharmacological agent. It may be added to cell culture medium as an exogenous spike to test the efficiency of extraction and detection methods, but it is not used as a treatment to modulate cellular responses. The parent compound PGF1alpha, not the metabolite, would be used in cell-based assays to study FP receptor activation and downstream signaling.
|
| Animal Protocol |
Not applicable. 13,14-Dihydro-15-keto PGF1alpha is an analytical standard, not a compound administered to animals in efficacy studies. It may be used as a spike-in standard for the analysis of biological samples from animals treated with PGF1alpha or other prostaglandins. In such studies, plasma or urine samples from experimental animals are spiked with the isotope-labeled internal standard, extracted, and analyzed by LC-MS/MS to quantify endogenous metabolite levels. The standard itself is not administered.
|
| ADME/Pharmacokinetics |
Not applicable. 13,14-Dihydro-15-keto PGF1alpha is an analytical standard, not a drug candidate. Pharmacokinetic studies are not performed on this compound. Its concentration in biological samples is measured as an indicator of PGF1alpha metabolism. The compound is an inactive metabolite with a short half-life in circulation (minutes), as it is further metabolized and excreted in urine. No formal PK parameters are available.
|
| Toxicity/Toxicokinetics |
No toxicity data is available. 13,14-Dihydro-15-keto PGF1alpha is an inactive endogenous metabolite and an analytical standard. It is not considered toxic at the concentrations used in analytical chemistry (nanograms to micrograms per mL). Standard laboratory safety practices for handling chemical reference standards should be followed. For research use only, not for human consumption.
|
| References | |
| Additional Infomation |
13,14-Dihydro-15-keto PGF1alpha (CAS: 29044-75-5) has molecular formula C20H34O4 and molecular weight 338.48. Also known as 11alpha,16-dihydroxy-9,15-dioxoprostanoate. It is a major metabolite of PGF1alpha produced by 15-PGDH and delta13,14-reductase. This product is intended for use as an analytical standard for the quantification of prostaglandin metabolites in research applications. For research use only, not for human therapeutic or diagnostic use.
|
| Molecular Formula |
C20H36O5
|
|---|---|
| Molecular Weight |
356.50
|
| Exact Mass |
356.256
|
| CAS # |
29044-75-5
|
| PubChem CID |
16061100
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
538.2±35.0 °C at 760 mmHg
|
| Flash Point |
293.4±22.4 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.5
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
25
|
| Complexity |
396
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCCC(=O)CC[C@@H]1[C@@H](CCCCCCC(=O)O)[C@H](C[C@H]1O)O
|
| InChi Key |
FVPKMMQYALWZHV-AKHDSKFASA-N
|
| InChi Code |
InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h16-19,22-23H,2-14H2,1H3,(H,24,25)/t16-,17-,18+,19-/m1/s1
|
| Chemical Name |
7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]heptanoic acid
|
| Synonyms |
Dihydro-15-oxoprostaglandin F1α
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8050 mL | 14.0252 mL | 28.0505 mL | |
| 5 mM | 0.5610 mL | 2.8050 mL | 5.6101 mL | |
| 10 mM | 0.2805 mL | 1.4025 mL | 2.8050 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
